Simulation of tissue activity curves of 64Cu-ATSM for sub-target volume delineation in radiotherapy

Physics in Medicine and Biology

Volumn 55, Issue 3, 2010, Pages 681-694

  Dalah, E ^a   Bradley, D ^a   Nisbet, A ^a,b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR UPTAKE; HIGH CONTRAST; MULTI-STEP; PET DATA; PET TRACER; RADIOTHERAPY TREATMENT PLANNING; REACTION DIFFUSION EQUATIONS; SIMULATION RESULT; SINGLE-STEP PROCESS; TARGET VOLUME DELINEATION; THEORETICAL STUDY; TIME FRAME; TISSUE CELLS; TRACER CONCENTRATION; VASCULATURE STRUCTURES;

OXYGENATION; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY;

TUMORS;

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; CONTRAST MEDIUM; COPPER; COPPER (II) DIACETYL DI(N(4) METHYLTHIOSEMICARBAZONE); COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); DRUG DERIVATIVE; MISONIDAZOLE; ORGANOMETALLIC COMPOUND; OXYGEN; THIOSEMICARBAZONE DERIVATIVE;

ALGORITHM; ARTICLE; BIOLOGICAL MODEL; BLOOD VESSEL; CELL HYPOXIA; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER SIMULATION; DIFFUSION; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY; VASCULARIZATION;

ALGORITHMS; BLOOD VESSELS; CELL HYPOXIA; COMPUTER SIMULATION; CONTRAST MEDIA; COPPER RADIOISOTOPES; DIFFUSION; HUMANS; MISONIDAZOLE; MODELS, BIOLOGICAL; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; THIOSEMICARBAZONES;

EID: 76149130433     PISSN: 00319155     EISSN: 13616560     Source Type: Journal    
DOI: 10.1088/0031-9155/55/3/009     Document Type: Article

References (41)

1. Aft R, Lewis J, Zhang F, Kim J and Welch M 2003 Enhancing targeted radiotherapy by copper(II)diacetylbis(N4-methylthiosemicarbazone) using 2-Deoxy-D-Glucose Cancer Res. 63 5496-504 (Pubitemid 37139869)
2. 18F] fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography Br. J. Cancer 90 2232-42
3. Basken N E and Green M A 2009 Cu(II) bis(thiosemicarbazone) radiopharmaceutical binding to serum albumin: further definition of species dependence and associated substituent effects Nucl. Med. Biol. 36 495-504
4. Beckman R, Weiner L and Davis H 2007 Antibody constructs in cancer therapy Cancer 109 170-9
5. Berk D, Yuan M and Jain R 1993 Fluorescence photobleaching with spatial fourier analysis: measurement of diffusion in light-scattering media Biophys. J. 65 2428-38
6. Chao K S C, Bosch W R, Mutic S, Lewis J S, Dehdashti F, Mintun M A, Dempsey J F, Perez C A, Purdy J A and Welch M J 2001 A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 49 1171-82
7. Cowan D, Hick K and Wilson W 1996 Multicellular membranes as an in vitro model for extravascular diffusion in tumours Br. J. Cancer 27 28-31
8. Cussler E 1984 Diffusion: Mass Transfer in Fluid Systems (Cambridge: Cambridge University Press)
9. Cutler C S, Lewis J S and Anderson C J 1999 Utilization of metabolic, transport and receptor-mediated processes to deliver agents for cancer diagnosis Adv. Drug Delivery Rev. 37 189-211
10. 2 partial pressure in 2D vasculature using the reaction diffusion model Phys. Med. Biol. submitted
11. Dence C, Ponde D, Welch M and Lewis J 2008 Autoradiographic and small-animal PET comparisons between 18F-FMISO, 18F-FDG, 18F-FLT and the hypoxic selective 64Cu-ATSM in a rodent model of cancer Nucl. Med. Biol. 35 713-20
12. Fischkoff S and Vanderkool J 1975 Oxygen diffusion in biological and artificial membranes determined by the fluorochrome pyrene J. Gen. Physiol. 65 663-76
13. Fukui B, Blodgett M and Meltzer C 2003 PET/CT imaging in recurrent head and neck cancer Semin. Ultrasound CT MRI 24 157-63
14. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J and Yokoyama A 1997 Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential J. Nucl. Med. 38 1155-60
15. Goshen E, Davidson T, Yahalom R, Talmi Y and Zwas S 2006 PET/CT in the evaluation of patients with squamous cells cancer of the head and neck Int. J. Oral Maxillofac. Surg. 35 332-6
16. Gregoire V, Haustermans K, Geets X, Roels S and Lonneux M 2007 PET-based treatment planning in radiotherapy: a new standard? J. Nucl. Med. 48 68S-77S
17. Huang C, Yu X, Bading J and Conti P 1998 Feature extraction by subspace fitting of time activity curve in PET dynamic studies IEEE 2 1721-5
18. Kelly C and Brady M 2006 A model to simulate tumour oxygenation and dynamic [18F]-FMISO PET data Phys. Med. Biol. 51 5859-73
19. Kim S and Sue T 2006 Imaging in radiation therapy Nucl. Eng. Technol. 38 327-38
20. Laidler K 1978 Physical Chemistry with Biological Applications (New York: Benjamin/Cummings)
21. 18F]fluoroerythronitoimidazole PET J. Nucl. Med. 42 1643-52
22. 64Cu-ATSM in vitro and in vivo in hypoxia tumour model J. Nucl. Med. 40 177-83
23. 4N-mehylthiosemicarbazone): an agent for radiotherapy J. Nucl. Med. 98 1206-11
24. Marieb E 2004 Human Anatomy and Physiology 6th edn (New York: Benjamin Cummings)
25. McCarthy D, Bass L, Cutler D, Shefer R, Klinkowstein R, Herrero P, Lewis J, Cutler C, Anderson C and Welch M 1999 High purity production and potential applications of copper-60 and copper-61 Nucl. Med. Biol. 26 351-8
26. 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents Nucl. Med. Biol. 32 147-56
27. 60Cu]ATSM in human neoplasms J. Nucl. Med. 41 58 Ref Type: Abstract
28. 64Cu-ATSM as a radiotherapy agent Nucl. Med. Biol. 32 21-8
29. Obata A et al 2003 Intra-tumoral distribution of 64Cu-ATSM: a comparison study with FDG Nucl. Med. Biol. 30 529-34
30. Oh M, Tanaka T, Kobayashi M, Furukawa T, Mori T, Kudo T, Fujieda S and Fujibayashi Y 2009 Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model Nucl. Med. Biol. 36 419-26
31. Padhani A, Krohn K, Lewis J and Alber M 2007 Imaging oxygenation of human tumours Eur. J. Radiol. 17 861-72
32. Rasey J, Casciari J, Hofstrand P, Muzi M, Graham M and Chin L 2000 Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole Radiat. Res. 53 84-92
33. Rothschild S, Studer G, Seifert B, Huguenin P, Glanzmann G, Davis B, Lütlof U, Hany T and Ceiernik F 2007 PET/CT staging followed by intensity modulated radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma a matched-pair comparison Radiat. Oncol. 2 1-10
34. Salathè E and Kolkka R 1986 Reduction of anoxia through myoglobin-facilitated diffusion of oxygen J. Biophys. Soc. 50 885-94
35. Sokoloff L, Reivich M, Kennedy C, Des Rosiers M H, Patlak C S, Pettigrew K D, Sakurada O and Shinohara M 1977 J. Neurochem. 28 897-916
36. Tanaka T, Furukawa T, Fujieda S, Kasamatsu S, Yonekura Y and Fujibayashi Y 2006 Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumour models Nucl. Med. Biol. 33 743-50
37. Thorwarth D, Eschmann S M, Paulsen F and Alber M 2007 Hypoxia dose painting by numbers: a planning study Int. J. Radiat. Oncol. Biol. Phys. 68 291-300
38. Vavere A and Lewis J 2007 Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia J. R. Soc. Chem. 43 4893-902
39. Wood K, Wang W and Saunders M 2008 [64Cu]diacetyl-bis(N4-methyl- thiosemicarbazone)-a radiotracer for tumour hypoxia Nucl. Med. Biol. 35 393-400
40. Yuan F, Dellian M, Fukumura D, Leunig M, Berk D, Torchilin V and Jain R 1995 Vascular permeability in human tumour xenograft: molecular size dependence and cutoff size Cancer Res. 55 3752-6
41. 4-methylthiosemicabazone) J. Nucl. Med. 47 989-98